Terns Pharmaceuticals Reports Positive Phase 1 Results of TERN-601 for Obesity Treatment
Overview of TERN-601 Clinical Trials
Terns Pharmaceuticals has successfully conducted a Phase 1 clinical trial evaluating TERN-601, a once-daily oral GLP-1R agonist tailored for the treatment of obesity. The trial reported remarkable results, indicating statistical significance in mean weight loss.
Results and Efficacy
The results revealed an impressive mean weight loss of 5.5% over the span of 28 days, adjusted for a placebo which showcased a 4.9% difference. This positions TERN-601 as a promising candidate in the obesity therapeutic landscape.
Tolerability and Safety
- Well tolerated: Patients reported minimal side effects.
- No treatment-related dose limiting: Factors were identified that could skew outcomes.
These findings highlight the potential of TERN-601 not just as a weight management solution but as a new frontier in obesity treatment therapies.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.